JP5581490B2 - 抗体媒介による細菌のクオラムセンシングの破壊 - Google Patents

抗体媒介による細菌のクオラムセンシングの破壊 Download PDF

Info

Publication number
JP5581490B2
JP5581490B2 JP2010531058A JP2010531058A JP5581490B2 JP 5581490 B2 JP5581490 B2 JP 5581490B2 JP 2010531058 A JP2010531058 A JP 2010531058A JP 2010531058 A JP2010531058 A JP 2010531058A JP 5581490 B2 JP5581490 B2 JP 5581490B2
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
aureus
molecular entity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010531058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500814A5 (cg-RX-API-DMAC10.html
JP2011500814A (ja
Inventor
キム ディー． ジャンダ
グナー エフ． カウフマン
ジュングック パーク
Original Assignee
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2011500814A publication Critical patent/JP2011500814A/ja
Publication of JP2011500814A5 publication Critical patent/JP2011500814A5/ja
Application granted granted Critical
Publication of JP5581490B2 publication Critical patent/JP5581490B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2010531058A 2007-10-25 2008-10-24 抗体媒介による細菌のクオラムセンシングの破壊 Expired - Fee Related JP5581490B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98259307P 2007-10-25 2007-10-25
US60/982,593 2007-10-25
PCT/US2008/012151 WO2009055054A2 (en) 2007-10-25 2008-10-24 Antibody-mediated disruption of quorum sensing in bacteria

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014124700A Division JP6183910B2 (ja) 2007-10-25 2014-06-17 抗体媒介による細菌のクオラムセンシングの破壊

Publications (3)

Publication Number Publication Date
JP2011500814A JP2011500814A (ja) 2011-01-06
JP2011500814A5 JP2011500814A5 (cg-RX-API-DMAC10.html) 2011-06-02
JP5581490B2 true JP5581490B2 (ja) 2014-09-03

Family

ID=40580303

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010531058A Expired - Fee Related JP5581490B2 (ja) 2007-10-25 2008-10-24 抗体媒介による細菌のクオラムセンシングの破壊
JP2014124700A Expired - Fee Related JP6183910B2 (ja) 2007-10-25 2014-06-17 抗体媒介による細菌のクオラムセンシングの破壊
JP2017140405A Pending JP2018021021A (ja) 2007-10-25 2017-07-19 抗体媒介による細菌のクオラムセンシングの破壊

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014124700A Expired - Fee Related JP6183910B2 (ja) 2007-10-25 2014-06-17 抗体媒介による細菌のクオラムセンシングの破壊
JP2017140405A Pending JP2018021021A (ja) 2007-10-25 2017-07-19 抗体媒介による細菌のクオラムセンシングの破壊

Country Status (9)

Country Link
US (2) US9394371B2 (cg-RX-API-DMAC10.html)
EP (2) EP2842565B1 (cg-RX-API-DMAC10.html)
JP (3) JP5581490B2 (cg-RX-API-DMAC10.html)
KR (1) KR101557173B1 (cg-RX-API-DMAC10.html)
CN (2) CN104211775A (cg-RX-API-DMAC10.html)
AU (1) AU2008317331B2 (cg-RX-API-DMAC10.html)
CA (2) CA2975568A1 (cg-RX-API-DMAC10.html)
ES (1) ES2603061T3 (cg-RX-API-DMAC10.html)
WO (1) WO2009055054A2 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6445442B2 (ja) 2012-10-26 2018-12-26 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ａｉｐ２を結合する抗感染症結合タンパク質
DE102013211850A1 (de) * 2013-06-21 2014-12-24 Gilupi Gmbh Schnelltest zum Nachweisen von Erregermaterial, insbesondere zur Unterstützung der Diagnose einer Sepsis, sowie Kit und Vorrichtung zur Durchführung eines Sepsistests
AU2014298373B2 (en) * 2013-08-01 2019-12-05 Ludwig Institute For Cancer Research Ltd Anti-GARP protein and uses thereof
JP2017509587A (ja) 2013-12-27 2017-04-06 ノーバス・インターナショナル・インコーポレイテッドＮｏｖｕｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ，Ｉｎｃ． エトキシル化界面活性剤
JP6517156B2 (ja) * 2014-01-29 2019-05-22 Ｋｍバイオロジクス株式会社 抗トランスサイレチンヒト抗体
CN106574258B (zh) 2014-01-29 2021-03-30 Km生物医药股份公司 抗-运甲状腺素蛋白人源化抗体
EP3103808B1 (en) 2014-02-07 2018-08-22 Miyarisan Pharmaceutical Co., Ltd. Peptide having activity of inhibiting production of toxin by bacterium belonging to genus clostridium
WO2017136400A1 (en) * 2016-02-02 2017-08-10 Stc. Unm Vlp-based vaccines for targeting staphylococcus aureus secreted virulence factors
US12662513B2 (en) * 2016-05-01 2026-06-23 Wisconsin Alumni Research Foundation Peptidic modulators of quorum sensing in Staphylococcus epidermidis
US10808010B2 (en) 2016-08-11 2020-10-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide inhibitors of phosphoglycerate mutase and methods of use
US10836810B2 (en) 2017-02-17 2020-11-17 Mapp Biopharmaceutical, Inc. Monoclonal antibodies and cocktails for treatment of ebola infections
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
US20210177917A1 (en) * 2017-08-31 2021-06-17 The Regents Of The University Of California Molecular bacteriotherapy to control skin enzymatic activity
JP7035170B2 (ja) 2017-09-15 2022-03-14 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ１９免疫療法によりがんを処置するための組成物および方法
US10774135B2 (en) 2017-12-22 2020-09-15 Sorrento Therapeutics, Inc. Variant antibodies that bind AIP2
JP7290146B2 (ja) 2018-02-13 2023-06-13 住友化学株式会社 組成物および成形体
EP4013372A4 (en) 2019-08-13 2023-08-30 McCord, Darlene E. Non-activated, amorphous, ph neutral, two-part bedside-ready clay delivery system that treats pathogen infections in humans and animals
CN111573853B (zh) * 2020-05-29 2020-11-20 南京大学 一种削减生物法处理废水毒性的方法
WO2023076855A1 (en) 2021-10-25 2023-05-04 Mccord Darlene E Coated medicinal clay compositions, pharmaceutical compositions, and delivery of cation sources and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044349A1 (en) * 1996-05-22 1997-11-27 New York University BLOCKING EXPRESSION OF VIRULENCE FACTORS IN $i(S. AUREUS)
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6559176B1 (en) * 2000-05-10 2003-05-06 Princeton University Compounds and methods for regulating bacterial growth and pathogenesis
US7786257B2 (en) * 2000-12-18 2010-08-31 University Of Kansas Signal-1/signal-2 bifunctional peptide inhibitors
US6463632B2 (en) * 2001-02-07 2002-10-15 Hans Oetiker Ag Maschinen-Und Apparatefabrik Guide arrangement for tightening tool emplacement in hose clamps provided with plastically deformable ears
CN1164612C (zh) * 2001-09-11 2004-09-01 四川新泰克控股有限责任公司 人工组合的抗菌工程多肽及其制备方法
JP4630663B2 (ja) * 2002-08-13 2011-02-09 ハプトゲン リミテッド 抗ラクトンシグナル分子抗体または抗ラクトン由来シグナル分子抗体による感染性細菌症の治療のための方法

Also Published As

Publication number Publication date
KR101557173B1 (ko) 2015-10-05
US9394371B2 (en) 2016-07-19
WO2009055054A2 (en) 2009-04-30
EP2211889A2 (en) 2010-08-04
ES2603061T3 (es) 2017-02-23
JP2011500814A (ja) 2011-01-06
JP6183910B2 (ja) 2017-08-23
CA2703133C (en) 2017-09-19
AU2008317331B2 (en) 2013-08-29
KR20100102100A (ko) 2010-09-20
EP2842565A1 (en) 2015-03-04
WO2009055054A3 (en) 2009-09-03
EP2211889B1 (en) 2014-08-20
JP2014221774A (ja) 2014-11-27
US20100291093A1 (en) 2010-11-18
US20170043020A1 (en) 2017-02-16
JP2018021021A (ja) 2018-02-08
CN101835484B (zh) 2014-07-16
CN101835484A (zh) 2010-09-15
CA2703133A1 (en) 2009-04-30
AU2008317331A1 (en) 2009-04-30
CA2975568A1 (en) 2009-04-30
EP2211889A4 (en) 2012-01-11
CN104211775A (zh) 2014-12-17
EP2842565B1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
JP6183910B2 (ja) 抗体媒介による細菌のクオラムセンシングの破壊
ES2372686T3 (es) Anitcuerpos monoclonales dirigidos contra la proteína clfa y modo de empleo en el tratamiento y prevención de infecciones.
AU2004258797B2 (en) Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
US20110059098A1 (en) Human Anthrax Toxin Neutralizing Monoclonal Antibodies and Methods of Use Thereof
US20020159997A1 (en) Staphylococcal immunotherapeutics via donor selection and donor stimulation
JP2002523474A (ja) ドナーの選択およびドナーの刺激によるブドウ球菌の免疫療法
US20020169288A1 (en) Collagen-binding adhesin from staphylococcus epidermidis and method of use
JP2007504279A6 (ja) ブドウ球菌およびその他の細菌の感染に対する治療および予防の方法およびその組成物
CA2420287A1 (en) Anthrax specific antibodies
JP2011046705A (ja) 抗ラクトンシグナル分子抗体または抗ラクトン由来シグナル分子抗体による感染性細菌症の治療のための方法
KR20210035846A (ko) 에스. 아우레우스 클럼핑 인자 A(ClFA)에 지향되는 항체
HUE025378T2 (hu) Keresztreagáló Staphylococcus aureus ellenanyag
KR20100028558A (ko) 녹농균 외막 단백질 ｐａ4710
CN104797597A (zh) 针对胞壁肽的单克隆抗体
CN117396502A (zh) 针对肺炎球菌抗原的人类单克隆抗体
Lenkey Using phage display to select peptides binding to type 8 capsular polysaccharide of Staphylococcus aureus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140519

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140618

R150 Certificate of patent or registration of utility model

Ref document number: 5581490

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees